How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation document.docx

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about selinexor

Marketing authorisation indication

2.1

Selinexor (Nexpovio, Menarini Stemline) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy'.

Price

2.3

The list price for selinexor is £14,720 per 32-tablet pack of 20-mg tablets (excluding VAT; company submission). Other pack sizes are available. The list price of selinexor is £9,200 per 28-day cycle of treatment on standard dosage.

2.4

The company has a commercial arrangement (simple patient access scheme). This makes selinexor available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.